IMMUNOGLOBULIN A TEST SYSTEM

K990552 · Dade Behring, Inc. · CFQ · Mar 25, 1999 · Immunology

Device Facts

• Record ID: K990552
• Device Name: IMMUNOGLOBULIN A TEST SYSTEM
• Applicant: Dade Behring, Inc.
• Product Code: CFQ · Immunology
• Decision Date: Mar 25, 1999
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 866.5510
• Device Class: Class 2

Intended Use

The IGA Flex™ reagent cartridge is used in the Dimension® clinical chemistry system to quantitatively measure immunoglobulin A (IgA) in serum and plasma.

Device Story

The IGA Flex™ reagent cartridge is an in vitro diagnostic assay for the Dimension® clinical chemistry system. It measures IgA concentration in serum or plasma samples via a turbidimetric immunoprecipitation method. The device utilizes polyclonal antibodies to react with IgA, forming an immunoprecipitate; polyethylene glycol is added to accelerate this formation. The system performs bichromatic endpoint measurements at 340 and 700 nm to detect turbidity. The resulting turbidity increase is proportional to IgA concentration, which is calculated by the system using a five-point calibration curve. The device is intended for use in clinical laboratory settings by trained personnel. The output provides quantitative IgA levels, assisting clinicians in the assessment of immunoglobulin status.

Clinical Evidence

Clinical performance was evaluated via a split-sample comparison between the IGA Flex™ reagent cartridge and the predicate Beckman Array® IgA assay. Testing was performed on 100 clinical patient samples. Results showed a correlation coefficient of 0.983, a slope of 0.96, and an intercept of 3.4 mg/dL, supporting substantial equivalence.

Technological Characteristics

Quantitative turbidimetric assay; utilizes polyclonal antibodies and polyethylene glycol; bichromatic endpoint measurement at 340 and 700 nm; five-point calibration curve; designed for use on the Dimension® clinical chemistry system.

Indications for Use

Indicated for the quantitative measurement of immunoglobulin A (IgA) in human serum and plasma samples using the Dimension® clinical chemistry system. For prescription use only.

Regulatory Classification

Identification

An immunoglobulins A, G, M, D, and E immunological test system is a device that consists of the reagents used to measure by immunochemical techniques the immunoglobulins A, G, M, D, an E (serum antibodies) in serum. Measurement of these immunoglobulins aids in the diagnosis of abnormal protein metabolism and the body's lack of ability to resist infectious agents.

Predicate Devices

• Beckman Array® Immunoglobulin A Method (K922273)

Submission Summary (Full Text)

{0}------------------------------------------------

3/25/99

K990552

# DADE BEHRING

DADE BEHRING INC. P.O. Box 6101 Newark, DE 19714

#### Summary of Safety and Effectiveness Information

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

| Submitter's Name: | Cathy P. Craft<br>Dade Behring Inc.<br>P.O. Box 6101<br>Newark, DE 19714-6101 |
|--------------------------|-------------------------------------------------------------------------------|
| Date of Preparation: | February 16, 1999 |
| Name of Product: | IGA Flex™ Reagent Cartridge |
| FDA Classification Name: | Immunoglobulin A Test System |
| Predicate Device: | Beckman Array® Immunoglobulin A Method (K922273) |

Device Description: The IGA Flex™ reagent cartridge for the Dimension® clinical chemistry system is a quantitative, turbidimetric assay based on the precipitation of IgA by its polyclonal antibodies.a

IgA from serum or plasma reacts with its polyclonal antibodies to form an immunoprecipitate. Addition of polyethylene glycol accelerates the formation of the precipitate. Turbidity created by immunoprecipitation is measured as bichromatic endpoint measurements at 340 and 700 um. The increase in turbidity is proportional to the concentration of IgA and it is calculated from a five point calibration curve.

> PEG IgA + Antibody ------------------------> IgA-Antibody Complex

a The antibody is manufactured by Dade Behring, Marburg, Germany

Intended Use: The IGA Flex™ reagent cartridge is used in the Dimension® clinical chemistry system to quantitatively measure immunoglobulin A (IgA) in serum and plasma.

#### Comparison to Predicate Device:

| Item | IGA Flex™ Reagent Cartridge | Beckman Array® IgA |
|-------------|------------------------------------------------------------|--------------------------|
| Sample Type | Serum and plasma | Serum |
| Methodology | Immunoprecipitation | Immunoprecipitation |
| Detection | Bichromatic endpoint<br>(340 and 700 nm)<br>(turbidimetry) | Nephelometry<br>(405 nm) |

{1}------------------------------------------------

## Comments on Substantial Equivalence:

Split sample comparison between the IGA Flex™ reagent cartridge and the Beckman Immunoglobulin A assay gave a correlation coefficient of 0.983, slope of 0.96, and an intercept of 3.4 mg/dL when tested with 100 clinical patient samples.

The IGA Flex™ reagent cartridge is substantially equivalent in principle and Conclusion: performance to the Beckman Immunoglobulin A Assay based on the split sample comparison discussed above.

Cathy P. Swift

Cathy P. Craft Regulatory Affairs and Compliance Manager Date: February 16, 1999

{2}------------------------------------------------

MAR 2 5 1999

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Ms. Cathy P. Craft Regulatory Affairs and Compliance Manager DADE Behring, Inc. Chemistry Group P.O. Box 6101 Route 896, Glasgow Bldg. 500 Newark, Delaware 19714-6101

Re: K990552

Trade Name: DIMENSION® Immunoglobulin IgA FLEX™ Reagent Cartridge Regulatory Class: II Product Code: CFQ Dated: February 18, 1999 Received: February 22, 1999

Dear Ms. Craft:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

{3}------------------------------------------------

Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at [phone].

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number [phone] or [phone], or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Steven Putman

Steven I. Gutman, M.D, M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

Indications For Use Statement

Device Name: IGA Flex™ Reagent Cartridge

## Indications for Use:

The IGA Flex™ reagent cartridge for the Dimension® Clinical Chemistry System is an in vitro diagnostic device intended to quantitatively measure immunoglobulin A in serum and plasma.

> Cathy P. Craft Regulatory Affairs and Compliance Manager

February 16, 1999

# (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Peter E. Mason

(Division Sign-Off) Division of Clinical Lab 510(k) Number

Prescription Use L (Per 21 CFR 801.109)

---------

OR

Over-the counter Use (Optional format 1-2-96)